BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SH, Chung YH, Yang SH, Kim JA, Jang MK, Kim SE, Lee D, Lee SH, Lee D, Kim KM. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol. 2009;15:320-330. [PMID: 19783881 DOI: 10.3350/kjhep.2009.15.3.320] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
2 Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12954. [PMID: 30412113 DOI: 10.1097/MD.0000000000012954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012;130:2685-92. [PMID: 21780114 DOI: 10.1002/ijc.26301] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
4 El-din Bessa SS, Elwan NM, Suliman GAM, El-shourbagy SH. Clinical Significance of Plasma Osteopontin Level in Egyptian Patients with Hepatitis C Virus-related Hepatocellular Carcinoma. Archives of Medical Research 2010;41:541-7. [DOI: 10.1016/j.arcmed.2010.10.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
5 Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806-14. [PMID: 24247813 DOI: 10.1097/MCG.0000000000000018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
6 Ronald J, Nixon AB, Marin D, Gupta RT, Janas G, Chen W, Suhocki PV, Pabon-Ramos W, Sopko DR, Starr MD, Brady JC, Hurwitz HI, Kim CY. Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. Radiology 2017;285:311-8. [PMID: 28787261 DOI: 10.1148/radiol.2017162555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Khalil A, Elgedawy J, Faramawi MF, Elfert A, Salama I, Abbass A, Elsaid H, Elsebaai H. Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions. Tumori 2013;99:100-7. [DOI: 10.1177/030089161309900117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
8 Lee D, Jang MK, Seo JH, Ryu SH, Kim JA, Chung YH. ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications. Exp Mol Med 2018;50:1-12. [PMID: 30054466 DOI: 10.1038/s12276-018-0106-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Tampaki M, Doumba PP, Deutsch M, Koskinas J. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol 2015; 7(14): 1834-1842 [PMID: 26207165 DOI: 10.4254/wjh.v7.i14.1834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
10 Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, Chen MF, Tsai CN. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 2012;19 Suppl 3:S455-S463. [PMID: 21822558 DOI: 10.1245/s10434-011-1946-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
11 Wong K, Xu Z, Chen J, Lee NP, Luk JM. Circulating markers for prognosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 2013;7:319-29. [DOI: 10.1517/17530059.2013.795146] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
12 You Y, Zheng Q, Dong Y, Wang Y, Zhang L, Xue T, Xie X, Hu C, Wang Z, Chen R, Wang Y, Cui J, Ren Z. Higher Matrix Stiffness Upregulates Osteopontin Expression in Hepatocellular Carcinoma Cells Mediated by Integrin β1/GSK3β/β-Catenin Signaling Pathway. PLoS One 2015;10:e0134243. [PMID: 26280346 DOI: 10.1371/journal.pone.0134243] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
13 Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, Wu GH, Luk JM. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012; 18(30): 3923-3930 [PMID: 22912540 DOI: 10.3748/wjg.v18.i30.3923] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
14 Sun JY, Xu JM, Yan M, Ye F. Advances in understanding relationship between osteopontin and metastasis and recurrence of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(16): 1498-1504 [DOI: 10.11569/wcjd.v21.i16.1498] [Reference Citation Analysis]
15 Zhang R, Zhang Z, Pan X, Huang X, Huang Z, Zhang G. ATX-LPA Axis Induces Expression of OPN in Hepatic Cancer Cell SMMC7721. Anat Rec 2011;294:406-11. [DOI: 10.1002/ar.21324] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]